I-Epzicom (abacavir + lamivudine) - Ulwazi lweNtsholongwane kaGawulayo

Ukusetyenziswa kweziyobisi, iingqwalasela kunye nokuphikisana

I-Epzicom iyinambuzane echanekileyo yokudibanisa isilwanyana esisetyenziselwa unyango lwe-HIV, equlethwe ngama- antiretroviral agents , abacavir (Ziagen) kunye ne-lamivudine (i-Epivir). Zomibini izidakamizwa ezibandakanyekayo zibalwa njenge-nucleoside reverse transcriptase inhibitors (NRTIs) kwaye zisebenza ngokuthintela i-enzyme efunekayo ukuzalisa ukuhlanganiswa kwe-DNA yintsholongwane kwiseli yesifo.

Ngokwenza njalo, i-HIV ayikwazi ukuphindaphinda iphinde isasaze kwezinye iiseli.

I-Epzicom yavunywa ukuba isebenziswe ngabantu abadala ngabaphathi be-US Food and Drug Administration (i-FDA) ngo-Agasti 2, 2004. Ngaphandle kwe-US, isichengiselwano sithengiswa phantsi kwegama le- Kivexa .

UkuPhathwa kweziMilo

I-Epzicom ifumaneka kwifomu yeethebhulethi nge-600mg ye-abacavir kunye ne-300mg ye-lamivudine. Iipilisi ezifakwe kwifilimu ziyi-oblong ngesimo, i-orange, kunye ne "GS FC2" kwelinye icala.

Imilinganiselo

Ithebhulethi nganye imihla ngemihla ithathwa ngomlomo kunye okanye ngaphandle kokutya. I-Epzicom ayizange ithathwe yodwa kwaye kufuneka isetyenziswe ngonyango oludibeneyo kunye nenye okanye izidakamizwa ezininzi ze-antiretroviral.

Iziphumo eziPhakathi

Iziphumo eziqhelekileyo ezichaphazelekayo nokusetyenziswa kwe-Epzicom (ezenzeka kwiimeko ezingama-9%) ziquka:

Uninzi lweempawu zihlala zifutshane ngokukhawuleza nangona abantu abaneempawu ze-drug hypersensitivity kufuneka bafune unyango lwangoko.

Ukuxiliswa kweMithi yokuChengisa iMithi

Ngamanye amaxesha ukugqithiswa kwezidakamizwa kuboniswe kwizigulana ezichazwe kwii-regimens ze-abacavir ezineziyobisi kwaye zingaba zibulala xa zingashiywanga. Iphawulwe ngamabini amabini okanye ngaphezulu kwezi zibonakaliso ezilandelayo:

Iimpawu ze-hypersensitivity zibonakala ngokubanzi kwiiveki zokuqala ezi-6, nangona ziyakwazi ukubonakala naliphi na ixesha lokusetyenziswa kweziyobisi. Ngokuqhelekileyo, nangona kunjalo, iziganeko ezininzi ze-hypersensitivity zenzeka kwiintsuku ezili-10 zokuqala okanye njalo.

Ukuba i-hypersensitivity ikhunjulwa, i- Epzicom kufuneka imiswe ngokukhawuleza . Izigulane kufuneka zidibanise ngoko nangoko ugqirha kunye / okanye baye kwikliniki yabo okanye kwiindawo eziphuthumayo ngaphandle kokulibala.

Ngaphambi kokuba uqalise unyango nge-abacavir, ogqirha bayacetyiswa ukuba baqaphele i-HLA-B * 5701 ukuphela njengokuba izigulane ezile mihla yemfuza ziyaziwa ngokuba yingozi enkulu yokuba ne-abacavir hypersensitivity.

Ucwaningo lwezonyango luye lwabonisa ukuba malunga ne-8% yezigulane kwi-abacavir ziya kuba neempendulo zengqondo, ngamanye amaxesha zinzulu.

Ukungqinelana

Ukusebenzisana kweziyobisi

Kucetyiswa ukuba izigulane zinciphise utywala ngexesha lo-Epzicom, ngelixa izigulane kwi-methadone mazicebise ugqirha ukuba i-Epzicom imiselwe.

Ingqwalasela yonyango

Izigulane ezinesifo (impempo) ukukhubazeka akufanele zimiselwe i-Epzicom ukuba imvume yokudalila ingaphantsi kwe-50mL / ngomzuzu. Kwizigulane ezinobungozi bokungasebenzi kwemfucuza, zibandakanya imvume yokudalwa kwemveli, i-serum phosphorus, i-urine glucose kunye neprotheni yomchamo xa uqhuba iimvavanyo zokujonga rhoqo .

Nangona ezinye izifundo zezilwanyana ziphakanyisile ingozi eyingozi yokungabikho komzimba kwiisundu kunye noonogwaja abonakaliswe ku-abacavir okanye i-lamivudine, akukho nto yantlukwano kuye kwabikwa kwabasetyhini abakhulelweyo abachazwe kwiziyobisi ngokumalunga nalabo babantu bonke.

Kwihlabathi eliphuculweyo, kucetyiswa ukuba oomama abanentsholongwane kaGawulayo bayakuphepha ukuncelisa ngenxa yokunyuka kwengozi yokudlulisela i-HIV kwiintsana zabo.

Imithombo:

US Administration and Drug Administration (FDA). "I-FDA iyavuma ukuhlanganiswa kweziBini ezinokuThatyathwa kweDube iMichiza yeMithi yokuPhathwa kwe-HIV-1 Infection." Silver Spring, eMaryn; kukhutshwa ngo-Agasti 2, 2004.